港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

高瓴概念

536.305

-8.338-1.53%

涨家数：9

跌家数：41

平家数：5

市盈率：- -

高：548.851

开：544.657

低：534.195

收：544.643

数据加载中...

【摩根大通认股证牛熊证】美团暂录5连跌彭博报道指南非股东近日减持美团股份美团购(16290)/沽(18216)

阿斯达克财经

来凯医药-B(02105.HK)：LAE103的新药临床试验已获得美国食品药品监督管理局批准

康宁杰瑞制药-B(09966.HK)：JSKN003获美国FDA批准开展一项治疗不限HER2表达水平的PROC的II期临床研究

信义能源(03868.HK)根据以股代息计划发行7658.21万股代息股份

来凯医药-B：LAE103的新药临床试验(IND)已获得美国FDA批准

中金：维持微创医疗(00853.HK)“跑赢行业”评级升目标价至17港元

今年已有九只基金翻倍创新药主题基金强势领涨

聚焦临床痛点沛嘉医疗亮出多项重磅技术进展

微创医疗近7个交易日累涨近90%！近日获摩根大通增持，最新持股比例为10%

老虎资讯综合

三生制药涨超3% SSGJ-707出海绑定辉瑞海外估值提升潜力巨大

大行评级｜瑞银：上调中国平安目标价至66港元预测第二季新业务价值按年增长43%

锦欣生殖盘中涨超8% 政策红利逐步释放公司为民营辅助生殖龙头

美团创逾两周以来盘中新低！Prosus悄然减持2.5亿美元美团股票

老虎资讯综合

港股异动 | 有赞(08083)再涨超7% 预计上半年纯利最多7400万元同比实现扭亏为盈

李氏大药厂盘中异动大幅上涨5.49%报1.920港元

恒指跌超1%

信达生物涨1.78% 股价突破100港元大关

锦欣生殖盘中异动股价大涨5.56%报3.420港元

中信证券：政策信号明确关注医疗器械拐点机会

3 款创新药在中国获批，来自强生、阿斯利康、李氏大药厂

Insight数据库

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1583/news?page=10"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":536.3049,"timestamp":1754035689688,"preClose":544.6429,"halted":0,"volume":1273915179,"delay":0,"changeRate":-0.015309,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-8.338013,"latestTime":"08-01 16:00:00","open":544.6572,"high":548.851,"low":534.19507,"amount":21412358748.8,"amplitude":0.026909,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1754271000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1754011800000,1754020800000],[1754024400000,1754035200000]],"pbRate":2.560761,"peRate":23.337834,"turnoverRate":0.009141,"increases":6,"decrements":43,"flats":4,"marketCap":3097820304512,"floatMarketCap":2380639946624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":548.851,"amplitude":0.026909,"preClose":544.6429,"low":534.19507,"pbRate":"2.560761","latestPrice":536.3049,"volume":1273915179,"delay":0,"open":544.6572,"prevYearClose":446.93042,"prevWeekClose":548.862,"prevMonthClose":544.643,"prevQuarterClose":500.645,"fiveDayClose":548.862,"twentyDayClose":502.828,"sixtyDayClose":482.232,"secType":"PLATE","market":"HK","turnoverRate":0.009141,"peRate":23.337834,"marketCap":3097820304512,"floatMarketCap":2380639946624,"timestamp":1754035689688,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":9,"down":41,"flat":5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555185008","title":"【摩根大通认股证牛熊证】美团暂录5连跌  彭博报道指南非股东近日减持美团股份  美团购(16290)/沽(18216)","url":"https://stock-news.laohu8.com/highlight/detail?id=2555185008","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555185008?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 13:05","pubTimestamp":1753938300,"startTime":"0","endTime":"0","summary":"据《彭博通讯社》引述知情人士指，腾讯的南非大股东Naspers旗下Prosus近日开始减持于美团的持股，过去一段时间套现约2.5亿美元。公司计划推出新一轮规模最多达30亿美元的回购，并宣布派发第二季度的股息，每股10美仙。过往表现并不代表将来的表现，摩根大通不保证未来事件或表现将与上述任何意见或预测一致。任何人士均不得以此等资料作为向摩根大通提出任何申索或诉讼之根据。Nasdaq尚未认证该结构性产品的合法性或适用性。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211130113259481_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211130113259481_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1457448/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0605514214.HKD","BK1604","IE00BF5LJ272.USD","LU1152091168.USD","SG9999002463.SGD","BK1589","LU1993786604.SGD","BK1583","LU1960683339.HKD","METmain","LU0196878994.USD","LU0251144936.SGD","LU1102505762.USD","LU0143863784.USD","LU0823039010.USD","IE0032431581.USD","IE00B3M56506.USD","LU0320764755.SGD","LU1048596156.SGD","SG9999014674.SGD","03690","MPNGY","IE0008368742.USD","LU2476274720.SGD","HMTD.SI","LU0633140727.USD","LU1008478684.HKD","LU0828238088.HKD","BK1233","LU0918141887.USD","LU2242644610.SGD","LU0700851271.USD","LU2778985437.USD","LU0048580855.USD","LU0128522157.USD","LU0049853897.USD","LU0165289439.USD","LU2097828631.EUR","LU0819121731.USD","LU0106252389.USD","LU0345776255.USD","LU0359202008.SGD","LU0588545490.SGD","LU0634319403.HKD","LU0509642566.USD","LU0577902298.EUR","LU0417516738.SGD","LU0261950983.USD","LU1328277881.USD","LU2399975544.HKD"],"gpt_icon":1},{"id":"2555070823","title":"来凯医药-B(02105.HK)：LAE103的新药临床试验已获得美国食品药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2555070823","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555070823?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 12:27","pubTimestamp":1753936072,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02105","03347","BK1576","BK1161","BK1141"],"gpt_icon":0},{"id":"2555077032","title":"康宁杰瑞制药-B(09966.HK)：JSKN003获美国FDA批准开展一项治疗不限HER2表达水平的PROC的II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077032","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555077032?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 12:22","pubTimestamp":1753935770,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0737861772.HKD","03347","LU0329678170.USD","III","LU0329678337.USD","PROC","BK1574","BK1576","06078","BK1583","BK4007","BK4134","LU2488822045.USD","BK1161","BK1141","09966","BK1209"],"gpt_icon":0},{"id":"2555077437","title":"信义能源(03868.HK)根据以股代息计划发行7658.21万股代息股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555077437?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 12:13","pubTimestamp":1753935201,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1154","BK1554","BK1583","BK1594","03868"],"gpt_icon":0},{"id":"2555077764","title":"来凯医药-B：LAE103的新药临床试验(IND)已获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2555077764","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555077764?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 12:06","pubTimestamp":1753934760,"startTime":"0","endTime":"0","summary":"格隆汇7月31日丨来凯医药-B(02105.HK)宣布，LAE103的IND已获美国FDA批准。公司致力于为需要新型治疗方案的代谢疾病患者提供这种精准治疗。LAE103(一种针对Act RIIB的单克隆抗体)为公司自主研发、潜在用于治疗肌少性肥胖症及其他肌肉相关疾病。LAE103是一款Act RIIB选择性抗体。集团正积极推动该候选药物进入临床研究阶段，旨在为肌少性肥胖症及其他肌肉相关疾病提供创新疗法。追加内容本文作者可以追加内容哦 !","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731120856a6cacb59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731120856a6cacb59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1161","02105","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2555907203","title":"中金：维持微创医疗(00853.HK)“跑赢行业”评级 升目标价至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555907203","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555907203?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 11:33","pubTimestamp":1753932822,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WACC","00853","BK1100","BK1589","BK1585","159557","BK1583","DCF"],"gpt_icon":0},{"id":"2555072157","title":"今年已有九只基金翻倍 创新药主题基金强势领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2555072157","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555072157?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 11:08","pubTimestamp":1753931335,"startTime":"0","endTime":"0","summary":"Wind数据显示，截至目前，年内已有多达9只基金净值实现翻倍，其中业绩领先者收益率已接近140%，并因规模激增而暂停申购。业绩爆发，多只基金暂停大额申购在创新药板块的强劲上涨行情中，多只重仓该领域的基金抓住了市场机遇，净值表现惊人。为保护现有持有人的利益，该基金已于7月28日起暂停申购。7月29日，多只创新药主题ETF单日净申购额均超过2亿元，显示资金进场热情高涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111093694c52bcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073111093694c52bcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","06978","BK1593","01530"],"gpt_icon":1},{"id":"2555000782","title":"聚焦临床痛点 沛嘉医疗亮出多项重磅技术进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2555000782","media":"经济网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555000782?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 10:58","pubTimestamp":1753930714,"startTime":"0","endTime":"0","summary":"在神经介入领域，沛嘉医疗同样表现亮眼。在研产品进展成为本次开放日焦点。其中，TaurusTrio针对我国庞大的AR患者群体，已完成上市前临床并提交注册申请。据悉，单纯AR患者数量为主动脉瓣狭窄患者的2倍，近半数未获有效治疗，TaurusTrio预计2025年底至2026年初获批，届时将填补国内临床空白。面向未来，沛嘉医疗明确全球化战略，以临床需求为导向，持续深化精益管理，优化供应链体系，让更多创新医疗技术惠及中国乃至全球患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073116570694c5c84e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073116570694c5c84e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1574","09996","BK1583"],"gpt_icon":0},{"id":"1165862391","title":"微创医疗近7个交易日累涨近90%！近日获摩根大通增持，最新持股比例为10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165862391","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165862391?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 10:29","pubTimestamp":1753928952,"startTime":"0","endTime":"0","summary":"7月31日，$微创医疗(00853)$再涨逾7%，近7个交易日累涨近90%！近日获$摩根大通(JPM)$增持，最新持股比例为10%。","market":"hk","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微创医疗近7个交易日累涨近90%！近日获摩根大通增持，最新持股比例为10%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","LU0208291251.USD","BK1585","BK4585","LU0211326839.USD","LU0211328371.USD","LU0345769128.USD","BK1583","BK1100","LU0070302665.USD","IE00BJTD4N35.SGD","JPM","LU0345769631.USD","LU0234572021.USD","LU0345770308.USD","BK4207","LU0149725797.USD","IE00BYXW3230.USD","IE000M9KFDE8.USD","00853"],"gpt_icon":0},{"id":"2555744310","title":"三生制药涨超3% SSGJ-707出海绑定辉瑞 海外估值提升潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2555744310","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555744310?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 10:27","pubTimestamp":1753928878,"startTime":"0","endTime":"0","summary":"三生制药涨超3%，两个月累计涨幅逾1.6倍。截至发稿，涨2.82%，报32.8港元，成交额4.04亿港元。海通国际发布研报称，2025年7月，三生制药宣布与辉瑞就PD-1*VEGF双抗SSGJ-707达成的全球授权协议正式生效。该行认为，SSGJ-707中国销售峰值有望达到63-84亿元，全球销售峰值有望达到113-134亿美金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731104058a46c8e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731104058a46c8e17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01530","PFE","BK1161","BK1583"],"gpt_icon":1},{"id":"2555071257","title":"大行评级｜瑞银：上调中国平安目标价至66港元 预测第二季新业务价值按年增长43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555071257","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555071257?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 10:21","pubTimestamp":1753928487,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1880383366.USD","UBmain","IE00BMCWC346.EUR","LU0488056044.USD","IE00BZ08YR35.GBP","LU0348814723.USD","LU1515016050.SGD","HPAD.SI","IE0034224299.USD","ZTmain","LU0762541174.USD","LU1880383440.USD","LU0370786039.SGD","09983","LU1303224171.USD","PNGAY","IE0008368742.USD","LU0235996351.USD","82318","LU1146622755.USD","LU0821914370.USD","PAImain","601318","LU0630378692.HKD","LU0797268264.HKD","LU1226287529.USD","LU1719994722.HKD","LU2476274720.SGD","LU","LU0072462343.USD","SG9999002828.SGD","LU0197773160.USD","LU2348774022.SGD","02318","ZNmain","LU0067412154.USD","LU0417516902.SGD","03145","LU0348805143.USD","LU0588545490.SGD","BK1583","ZBmain","BK4504","LU0531971595.HKD","ZFmain","BK0070","LU1813983027.USD","LU1366334578.USD","TNmain","LU0831093199.SGD"],"gpt_icon":0},{"id":"2555074176","title":"锦欣生殖盘中涨超8% 政策红利逐步释放 公司为民营辅助生殖龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2555074176","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555074176?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 10:18","pubTimestamp":1753928290,"startTime":"0","endTime":"0","summary":"锦欣生殖盘中涨超8%，截至发稿，涨7.1%，报3.47港元，成交额6.41亿港元。海通国际近期研报指出，国内辅助生殖需求有望迎来拐点，政策红利逐步释放。2023-2025年辅助生殖纳入医保从区域试点扩展至全国，政策落地后需求释放可期。同时，该行认为行业供给侧格局趋稳，牌照发放收紧，公司作为民营辅助生殖龙头，有望通过三代试管婴儿牌照等技术优势和案例积累，优先承接增量需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731104048a6caa702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731104048a6caa702&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01951","BK1583","BK1219","BK1597"],"gpt_icon":0},{"id":"1105684052","title":"美团创逾两周以来盘中新低！Prosus悄然减持2.5亿美元美团股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1105684052","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105684052?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:58","pubTimestamp":1753927133,"startTime":"0","endTime":"0","summary":"7月31日，$美团-W(03690)$盘中跌幅扩大至近5%，创逾两周以来盘中新低！Prosus开始减持$美团(MPNGY)$股份，已减持约2.5亿美元。","market":"hk","thumbnail":"https://static.tigerbbs.com/e1238455e09ac8d1135014cb37eb0f4d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e1238455e09ac8d1135014cb37eb0f4d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美团创逾两周以来盘中新低！Prosus悄然减持2.5亿美元美团股票","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","LU0196878994.USD","LU0072462343.USD","IE0008368742.USD","BK4122","METmain","03690","BK1604","MPNGY","LU0049853897.USD","IE00B3M56506.USD","BK1521","LU0128522157.USD","BK1589","LU0052750758.USD","LU0072913022.USD","BK1583","BK4209","LU0048597586.USD","LU0054450605.USD"],"gpt_icon":1},{"id":"2555799030","title":"港股异动 | 有赞(08083)再涨超7% 预计上半年纯利最多7400万元 同比实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2555799030","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555799030?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:48","pubTimestamp":1753926491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，有赞再涨超7%，截至发稿，涨7.03%，报0.137港元，成交额1700.36万港元。消息面上，有赞发布公告，预计上半年收益约7.09亿至7.19亿元人民币，同比增加约3.3%至4.8%；净利润约6800万至7400万元人民币，去年同期为净亏损约人民币429.5万元，同比实现扭亏为盈，主要得益于整体收入提升；随着AI工具的广泛使用及经营效率提升，人均产出同比提高；及因历史收购形成的无形资产已于2024年年末完成摊销，相关费用影响消除。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1109","BK1590","BK1516","BK1518","08083"],"gpt_icon":0},{"id":"2555071731","title":"李氏大药厂盘中异动 大幅上涨5.49%报1.920港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555071731","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555071731?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:45","pubTimestamp":1753926318,"startTime":"0","endTime":"0","summary":"2025年07月31日早盘09时45分，李氏大药厂股票出现异动，股价快速拉升5.49%。截至发稿，该股报1.920港元/股，成交量125.45万股，换手率0.21%，振幅9.34%。资金方面，该股资金流入149.606万港元，流出65.3125万港元。李氏大药厂股票所在的药品行业中，整体涨幅为0.15%。其相关个股中，泰凌医药、中国同辐、李氏大药厂涨幅较大，振幅较大的相关个股有泰凌医药、中国同辐、李氏大药厂，振幅分别为26.32%、9.38%、9.34%。该公司主要在中国内地及中国香港开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073109451894c50379&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073109451894c50379&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00950","BK1587","06622","BK1583","BK1574"],"gpt_icon":0},{"id":"2555076469","title":"恒指跌超1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555076469","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555076469?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:32","pubTimestamp":1753925540,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0216","603259","LU1997244956.HKD","HSTECH","LU2242644610.SGD","MHImain","LU2125910500.SGD","02833","LU0320764599.SGD","LU1046422090.SGD","HHImain","HSImain","LU2328871848.SGD","YANG","LU1997245094.SGD","02359","LU1969619763.USD","LU0456842615.SGD","MCHmain","BK1141","513600","LU0708995583.HKD","HSI","LU2488822045.USD","LU2045819591.USD","LU1934453819.USD","BK1583","LU1979443071.USD","LU0052750758.USD","LU2495084118.USD","LU1997245177.USD","BK4614","BK1576"],"gpt_icon":0},{"id":"2555651079","title":"信达生物涨1.78% 股价突破100港元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2555651079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555651079?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:30","pubTimestamp":1753925420,"startTime":"0","endTime":"0","summary":"2025年07月31日早盘09时30分，信达生物股票出现异动，股价大幅上涨1.78%。截至发稿，该股报100.200港元/股，成交量56.3979万股，换手率0.03%，振幅1.52%。资金方面，该股资金流入3615.34万港元，流出437.173万港元。信达生物股票所在的药品行业中，整体涨幅为0.28%。该信息摘要如下：格隆汇7月28日｜香港交易所信息显示，贝莱德在信达生物的持股比例于07月22日从4.63%升至5.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093020a46c6b11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093020a46c6b11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1589","LU2488822045.USD","01801","BK1583","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2555079698","title":"锦欣生殖盘中异动 股价大涨5.56%报3.420港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555079698","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555079698?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 09:30","pubTimestamp":1753925417,"startTime":"0","endTime":"0","summary":"2025年07月31日早盘09时30分，锦欣生殖股票出现波动，股价急速拉升5.56%。截至发稿，该股报3.420港元/股，成交量953.85万股，换手率0.35%，振幅2.16%。资金方面，该股资金流入1161.31万港元，流出453.649万港元。锦欣生殖股票所在的生物技术行业中，整体跌幅为0.76%。其相关个股中，奥星生命科技、锦欣生殖、思路迪医药股份涨幅较大，振幅较大的相关个股有乐普生物-B、康宁杰瑞制药-B、药明巨诺-B，振幅分别为3.76%、2.69%、2.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093017a6ca845d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093017a6ca845d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1219","01951","BK1583","BK1597"],"gpt_icon":0},{"id":"2555707321","title":"中信证券：政策信号明确 关注医疗器械拐点机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2555707321","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555707321?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 08:18","pubTimestamp":1753921116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信证券发布研究报告称，近来高层多次提出“反内卷”、“集采优化不再唯低价论”支持创新药械等相关产业发展政策，医疗器械支付端改善，利于支持厂家集采后保持合理利润率，利好品牌力强、产品性能过硬的龙头企业在集采政策优化下份额提升。中投标破除唯低价论，中信证券认为价格端会逐步企稳，同时随着招标好转，预计部分企业25Q2业绩将向好，大部分企业将于25Q3好转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","BK1222","BK1100","LU2495084118.USD","LU1720050803.USD","BK0183","BK1583","LU2289578879.USD","LU1328615791.USD","09996","BK0196","600030","BK1564","LU1064130708.USD","BK0012","BK0188","BK1147","LU0405327148.USD","LU0405327494.USD","BK1516","159883","BK1521","LU1997245177.USD","LU1997245094.SGD","BK1574","LU1655091616.SGD","BK0276","09997","LU1997244956.HKD","06030","LU1064131003.USD","BK0028","LU1794554557.SGD"],"gpt_icon":0},{"id":"2555680075","title":"3 款创新药在中国获批，来自强生、阿斯利康、李氏大药厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2555680075","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555680075?lang=zh_cn&edition=fundamental","pubTime":"2025-07-31 08:09","pubTimestamp":1753920565,"startTime":"0","endTime":"0","summary":"2025 年 4 月 15 日，该药在中国首次获批上市，与常规治疗药物联合用于治疗抗乙酰胆碱受体抗体阳性的成人全身型重症肌无力患者。本次获批的是瑞利珠单抗在华申报的第二项适应症。2022 年 10 月，阿斯利康公布该试验的阳性结果。Insight 数据库显示，此前国内仅有 3 款新药获批用于 NMOSD，除阿斯利康的依库珠单抗之外，还有翰森制药引进的的 CD19 单抗“伊奈利珠单抗”和罗氏制药的 IL6R 单抗“萨特利珠单抗”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731082915a46c52b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731082915a46c52b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06622","BK1191","BK1587","AZN","BK1574","06978","BK1583","BK1161","JNJ","00950"],"gpt_icon":0}],"pageSize":20,"totalPage":54,"pageCount":10,"totalSize":1074,"code":"91000000","status":"200"}]}}